Halozyme Therapeutics (HALO) EBT Margin (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of EBT Margin data on file, last reported at 47.87% in Q1 2026.

• On a quarterly basis, EBT Margin fell 643.0% year-over-year to 47.87% in Q1 2026; TTM through Mar 2026 was 33.37%, a 2242.0% decrease from a year earlier, with the FY2025 full-year figure at 33.43%, down 2144.0% from the prior year.
• EBT Margin for Q1 2026 stood at 47.87%, up from 22.32% in the prior quarter.
• Over the last five years, EBT Margin for HALO reached as high as 63.45% in Q1 2022 and fell as low as 22.32% in Q4 2025.
• Historically, EBT Margin has averaged 43.77% across 5 years, with a median of 47.87% in 2026.
• Across the five-year window, EBT Margin jumped 3190 bps in 2022 and plunged 8212 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 39.0% in 2022, then increased by 13 bps to 43.98% in 2023, then soared by 36 bps to 59.8% in 2024, then sank by 137 bps to 22.32% in 2025, then jumped by 314 bps to 47.87% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 47.87% in Q1 2026, 22.32% in Q4 2025, and 61.81% in Q3 2025.